UNKNOWN and Sorrento Therapeutics (SRNE) merger information including expected completion date and offer price are displayed in the deal information table below.
This deal was abandoned on January 27, 2020
Sorrento Therapeutics (SRNE) Acquisition
The major Sorrento Therapeutics (SRNE) merger news updates & events are listed below. An invaluable data source for traders & investors looking to familiarize themselves with the ACQUIRER UNKNOWN takeover of Sorrento Therapeutics (SRNE) and trade the merger arbitrage spread. Following the acquisition news and events section, there is in-depth company profile. For more proprietary Merger Arbitrage Limited content and analysis on this buyout, follow this link Sorrento Therapeutics (SRNE). The current merger arbitrage spread is available on our Spread Tracker page.
Receive instant FREE access to constantly updated SRNE news related to the current merger deal. Simply register by entering your email address to receive weekly publication updates.
Traders can also review similar deal information on other stocks by selecting a deal from the “Deal” menu item above. Proprietary commentary can be accessed by simply entering a ticker symbol into the search box in the menu bar above such as “SRNE“, or click on a stock ticker in the tag cloud at the foot of this article. For broader takeover news on other constituents of the T20 portfolio, please see our Spread Tracker News feed.
Sorrento Therapeutics (NASDAQ: SRNE) Merger - Acquisition News and Events
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia.
It also develops CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; carcinoembryonic antigen CAR-T cell therapy for the treatment of liver metastases of pancreatic cancer; and various human antibodies. The company has a cooperation framework agreement with LifeTech Scientific Corporation for the research and development, production, and commercialization of water-soluble cannabidiol and other water-soluble cannabinoids products. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
